Skip to content
Review Open access

Resveratrol Modulates Bone Metabolism Through SIRT1‐Mediated NF‐κB Inhibition: Molecular Mechanisms and Therapeutic Implications

Nov 2026 · Cell Biochemistry and Function · Vol 44 · 0 citations · 110 references
Medicine

TL;DR

This review provides a mechanistic framework to evaluate resveratrol as a viable nutraceutical modality for the prevention and management of osteoporosis.

Abstract

ABSTRACT Osteoporosis and associated skeletal pathologies impose a staggering global health burden, disproportionately impacting elderly populations and postmenopausal women. At the root of excessive bone resorption and stalled osteogenesis lie persistent oxidative stress and chronic inflammation. Enter resveratrol, a naturally occurring polyphenol derived from red wine and grapes, which has surfaced as a compelling therapeutic candidate for skeletal preservation owing to its robust antioxidant and anti‐inflammatory capacities. Herein, we evaluate the molecular pathways through which resveratrol governs bone metabolism, focusing sharply on SIRT1‐driven suppression of NF‐κB signaling. Integrating findings across cell cultures, animal models, and clinical trials yields a unified perspective on these osteoprotective mechanisms. Dual benefits define resveratrol's impact on skeletal architecture: it stimulates osteoblast differentiation and mineralization while suppressing osteoclastogenesis and bone resorption. Primarily, these outcomes stem from the activation of SIRT1, a NAD + ‐dependent deacetylase acting as a negative regulator of NF‐κB transcription. Through SIRT1‐mediated deacetylation of the NF‐κB p65 subunit, the transcription of pro‐inflammatory cytokines including IL‐1β, TNF‐α, and IL‐6 diminishes, subsequently dampening RANKL‐driven osteoclastogenesis. Simultaneously, through the SIRT1‐dependent engagement of Nrf2/ARE pathways, antioxidant defenses are bolstered, sparing bone cells from oxidative stress‐induced apoptosis. Substantial preclinical promise notwithstanding, hurdles persist regarding both systemic bioavailability and the standardization of ideal dosing protocols for bone preservation. This review provides a mechanistic framework to evaluate resveratrol as a viable nutraceutical modality for the prevention and management of osteoporosis.

Read PDF

Similar papers

Review Open access Oct 2026

Oxidative Stress and Metabolic Reprogramming in Osteoclastogenesis: Molecular Mechanisms and Antioxidant Therapy for Bone Disorders

This review summarizes recent advances in the molecular mechanisms linking oxidative stress to osteoclast metabolism, focusing on ROS sources, mitochondrial dysfunction, redox-sensitive signaling pathways, endogenous antioxidant systems, and emerging antioxidant-based therapies.

Mohammad Ibtehaz Alam, F. Farhana, Tajiba Rahman Khan et al. · 0 citations
Open access Oct 2026

Polyol Pathway Inhibition by Epalrestat Attenuates Pathological Bone Loss through Redox Homeostasis and Sorbitol-Linked Calcium Signaling.

The contribution of polyol metabolism to pathological bone remodeling remains incompletely understood. Here, we examined its role in osteoclastogenesis and evaluated the skeletal effects of epalrestat, a clinically approved aldose reductase inhibitor. Exploratory single-cell analysis of two human femoral-head specimens...

Cheng-Lun Yao, Zi-Min Cai, Hai-Xin Song et al. · 0 citations
Review Open access Oct 2026

Epigenetic regulatory networks in the pathogenesis and treatment of osteoporosis subtypes

Osteoporosis is a systemic skeletal disorder characterized by reduced bone mineral density and heightened bone fragility, encompassing primary (senile and postmenopausal) and secondary (glucocorticoid-induced and diabetic) subtypes. Maintaining skeletal health relies on the dynamic balance between osteoblast-mediated b...

Zheng-Da Ren, Bing-Yang Dai, De-Quan Chen et al. · 0 citations
Open access Oct 2026

Thioredoxin‐2 Alleviates Osteoporosis by Restraining FOXO3a Nuclear Translocation

ABSTRACT Osteoporosis is a prevalent age‐ and disease‐associated skeletal disorder characterized by bone loss, remodeling imbalance, and vascular niche deterioration, yet how endothelial redox dysfunction drives this process remains unclear. Here, we identify mitochondrial thioredoxin‐2 (TRX2) as an endothelial safegua...

Chi Zhan, Zhao-Cai Zhou, Yue Ding et al. · 0 citations
Review Open access Oct 2026

Deciphering the Immune–Bone Interaction Network in Diabetic Bone Fragility: Inflammatory Mechanisms and Precision Therapeutics

Diabetes mellitus increases fracture risk and impairs skeletal repair even when bone mineral density is normal or elevated, indicating that diabetic bone fragility cannot be explained by bone mass alone. This review examines how chronic metabolic stress reshapes the immune–bone microenvironment and disrupts bone remode...

Wei-Xia Wang, Wei Xiong, Zheng Zhang · 0 citations
Review Open access Oct 2026

Advances in the regulation of osteoblast metabolic senescence and osteoporosis prevention by traditional Chinese medicine via the Wnt/β-catenin signaling network

Osteoporosis (OP) remains a therapeutic challenge, partly due to the limitations of the traditional “bone resorption–bone formation imbalance” paradigm. Although the Wnt signaling pathway is known to regulate bone metabolism, a systematic framework explaining how traditional Chinese medicine (TCM) corrects osteoblast d...

Jia-Hao Dong, Jie Su, Wei-Jie Yu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.